Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET Imaging of EGFR in colorectal tumor-bearing mice

Molecular Pharmaceutics

Volumn 11, Issue 11, 2014, Pages 3980-3987

  Zeng, Dexing ^a   Guo, Yunjun ^c,d   White, Alexander G ^a   Cai, Zhengxin ^a   Modi, Jalpa ^a   Ferdani, Riccardo ^c   Anderson, Carolyn J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b University of Pittsburgh   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY   (United States)

Author keywords

Cetuximab; Copper 64; Cross bridged chelator; Epidermal growth factor receptor; Metal free click chemistry; PET imaging

Indexed keywords

ALKYNE; AZIDE; CETUXIMAB; CHELATING AGENT; COPPER 64; EPIDERMAL GROWTH FACTOR RECEPTOR; N HYDROXYSUCCINIMIDE; TETRAXETAN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; COPPER; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CELL MEMBRANE; COLORECTAL TUMOR; CYCLOADDITION; DRUG CONJUGATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RENAL CLEARANCE; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG SCREENING; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PATHOLOGY; PROCEDURES; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CETUXIMAB; CHELATING AGENTS; COLORECTAL NEOPLASMS; COPPER RADIOISOTOPES; FEMALE; HUMANS; IMMUNOCONJUGATES; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84965184789     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500004m     Document Type: Article

References (34)

1. Schett, G.; Kiechl, S.; Redlich, K.; Oberhollenzer, F.; Weger, S.; Egger, G.; Mayr, A.; Jocher, J.; Xu, Q.; Pietschmann, P.; Teitelbaum, S.; Smolen, J.; Willeit, J. Soluble RANKL and Risk of Nontraumatic Fracture. JAMA, J. Am. Med. Assoc. 2004, 291, 1108-1113.
2. Herbst, R. S.; Shin, D. M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002, 94, 1593-1611.
3. Brabender, J.; Danenberg, K. D.; Metzger, R.; Schneider, P. M.; Park, J.; Salonga, D.; Holscher, A. H.; Danenberg, P. V. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin. Cancer Res. 2001, 7, 1850-1805.
4. Serrano, C.; Markman, B.; Tabernero, J. Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy. Cancer J. 2010, 16, 226-234.
5. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl. J. Med. 2004, 351, 337-345.
6. Jonker, D. J.; O'Callaghan, C. J.; Karapetis, C. S.; Zalcberg, J. R.; Tu, D.; Au, H. J.; Berry, S. R.; Krahn, M.; Price, T.; Simes, R. J.; Tebbutt, N. C.; van Hazel, G.; Wierzbicki, R.; Langer, C.; Moore, M. J. Cetuximab for the treatment of colorectal cancer. New Engl. J. Med. 2007, 357, 2040-2048.
7. Karapetis, C. S.; Khambata-Ford, S.; Jonker, D. J.; O'Callaghan, C. J.; Tu, D.; Tebbutt, N. C.; Simes, R. J.; Chalchal, H.; Shapiro, J. D.; Robitaille, S.; Price, T. J.; Shepherd, L.; Au, H. J.; Langer, C.; Moore, M. J.; Zalcberg, J. R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl. J. Med. 2008, 359, 1757-1765.
8. Wen, X.; Wu, Q. P.; Ke, S.; Ellis, L.; Charnsangavej, C.; Delpassand, A. S.; Wallace, S.; Li, C. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. J. Nucl. Med. 2001, 42, 1530-1537.
9. Schechter, N. R.; Wendt, R. E.; Yang, D. J.; Azhdarinia, A.; Erwin, W. D.; Stachowiak, A. M.; Broemeling, L. D.; Kim, E.E.; Cox, J. D.; Podoloff, D. A.; Ang, K. K. Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. J. Nucl. Med. 2004, 45, 1683-1687.
10. Li, W. P.; Meyer, L. A.; Capretto, D. A.; Sherman, C. D.; Anderson, C. J. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother. Radiopharm. 2008, 23, 158-171.
11. Perk, L. R.; Visser, G. W.; Vosjan, M. J.; Stigter-van Walsum, M.; Tijink, B. M.; Leemans, C. R.; van Dongen, G. A. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J. Nucl. Med. 2005, 46, 1898-1906.
12. Nayak, T. K.; Regino, C. A.; Wong, K. J.; Milenic, D. E.; Garmestani, K.; Baidoo, K. E.; Szajek, L. P.; Brechbiel, M. W. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A"-DTPA-cetuximab. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 1368-1376.
13. Anderson, C. J.; Jones, L. A.; Bass, L. A.; Sherman, E. L.; McCarthy, D. W.; Cutler, P. D.; Lanahan, M. V.; Cristel, M. E.; Lewis, J. S.; Schwarz, S. W. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J. Nucl. Med. 1998, 39, 1944-1951.
14. Connett, J. M.; Anderson, C. J.; Guo, L. W.; Schwarz, S. W.; Zinn, K. R.; Rogers, B. E.; Siegel, B. A.; Philpott, G. W.; Welch, M. J. Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 6814-6818.
15. Connett, J. M.; Buettner, T. L.; Anderson, C. J. Maximum tolerated dose and large tumor radioimmunotherapy studies of 64Cu-labeled monoclonal antibody 1A3 in a colon cancer model. Clin. Cancer Res. 1999, 5, 3207s-3212s.
16. 3-Octreotate in a Somatostatin Receptor-positive, Tumor-bearing Rat Model. Clin. Cancer Res. 1999, 5, 3608-3616.
17. Eiblmaier, M.; Meyer, L. A.; Watson, M. A.; Fracasso, P. M.; Pike, L. J.; Anderson, C. J. Correlating EGFR expression with receptorbinding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J. Nucl. Med. 2008, 49, 1472-1479.
18. Cai, W.; Chen, K.; He, L.; Cao, Q.; Koong, A.; Chen, X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 850-858.
19. Sprague, J. E.; Peng, Y.; Sun, X.; Weisman, G. R.; Wong, E. H.; Achilefu, S.; Anderson, C. J. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin. Cancer Res. 2004, 10, 8674-8682.
20. Wong, E. H.; Weisman, G. R.; Hill, D. C.; Reed, D. P.; Rogers, M. E.; Condon, J. P.; Fagan, M. A.; Calabrese, J. C.; Lam, K.-C.; Guzei, I. A.; Rheingold, A. L. Synthesis and Characterization of Cross-Bridged Cyclams and Pendant-Armed Derivatives and Structural Studies of their Copper(II) Complexes. J. Am. Chem. Soc. 2000, 122, 10561-10572.
21. Ferdani, R.; Stigers, D. J.; Fiamengo, A. L.; Wei, L.; Li, B. T.; Golen, J. A.; Rheingold, A. L.; Weisman, G. R.; Wong, E. H.; Anderson, C. J. Synthesis, Cu(II) complexation, 64Cu-labeling and biological evaluation of cross-bridged cyclam chelators with phosphonate pendant arms. Dalton Trans. 2012, 41, 1938-1950.
22. Zeng, D.; Ouyang, Q.; Cai, Z.; Xie, X. Q.; Anderson, C. J. New cross-bridged cyclam derivative CB-TE1K1P, an improved bifunctional chelator for copper radionuclides. Chem. Commun. 2014, 50, 43-45.
23. Guo, Y. J.; Ferdani, R.; Anderson, C. J. Preparation and Biological Evaluation of Cu-64 Labeled Tyr(3)-Octreotate Using a Phosphonic Acid-Based Cross-Bridged Macrocyclic Chelator. Bioconjugate Chem. 2012, 23, 1470-1477.
24. Sun, X.; Rossin, R.; Turner, J. L.; Becker, M. L.; Joralemon, M. J.; Welch, M. J.; Wooley, K. L. An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules 2005, 6, 2541-54.
25. Wang, M.; Caruano, A. L.; Lewis, M. R.; Meyer, L. A.; VanderWaal, R. P.; Anderson, C. J. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res. 2003, 63, 6864-6869.
26. Eiblmaier, M.; Meyer, L. A.; Anderson, C. J. The role of p53 in the trafficking of copper-64 to tumor cell nuclei. Cancer Biol. Ther. 2008, 7, 63-69.
27. Guo, Y.; Parry, J. J.; Laforest, R.; Rogers, B. E.; Anderson, C. J. The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer. J. Nucl. Med. 2013, 54, 1621-1629.
28. Mucha, A.; Grembecka, J.; Cierpicki, T.; Kafarski, P. Hydrolysis of the phosphonamidate bond in phosphono dipeptide analogues - The influence of the nature of the N-terminal functional group. Eur. J. Org. Chem. 2003, 24, 4797-4803.
29. Mucha, A.; Kunert, A.; Grembecka, J.; Pawelczak, M.; Kafarski, P. A phosphonamidate containing aromatic N-terminal amino group as inhibitor of leucine aminopeptidase - design, synthesis and stability. Eur. J. Org. Chem. 2006, 41, 768-772.
30. Wangler, C.; Schirrmacher, R.; Bartenstein, P.; Wangler, B. Click-chemistry reactions in radiopharmaceutical chemistry: fast & easy introduction of radiolabels into biomolecules for in vivo imaging. Curr. Med. Chem. 2010, 17, 1092-1116.
31. Zeng, D.; Zeglis, B. M.; Lewis, J. S.; Anderson, C. J. The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals. J. Nucl. Med. 2013, 54, 829-832.
32. Zeng, D.; Lee, N. S.; Liu, Y.; Zhou, D.; Dence, C. S.; Wooley, K. L.; Katzenellenbogen, J. A.; Welch, M. J. 64Cu Core-labeled nanoparticles with high specific activity via metal-free click chemistry. ACS Nano 2012, 6, 5209-5219.
33. Chen, K.; Wang, X. L.; Lin, W. Y.; Shen, C. K. F.; Yap, L. P.; Hughes, L. D.; Conti, P. S. Strain-Promoted Catalyst-Free Click Chemistry for Rapid Construction of Cu-64-Labeled PET Imaging Probes. ACS Med. Chem. Lett. 2012, 3, 1019-1023.
34. Stigers, D. J.; Ferdani, R.; Weisman, G. R.; Wong, E. H.; Anderson, C. J.; Golen, J. A.; Moore, C.; Rheingold, A. L. A new phosphonate pendant-armed cross-bridged tetraamine chelator accelerates copper(II) binding for radiopharmaceutical applications. Dalton Trans. 2010, 39, 1699-1701.